ClinicalTrials.gg
Sign In
RecruitingNCT06982573Updated Sep 19, 2025

The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients With ESRD

An interventional study of Effects of applying magnetic stimulation in End-Stage Renal Disease, sponsored by Bundang CHA Hospital. Recruiting at 1 site in South Korea. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.

Sponsored by Bundang CHA Hospital · Not applicable, Interventional, and Other

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Aug 2025; still recruiting 1 year 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
19 Years and older
Sex
All
01

Study summary

To determine the effectiveness of magnetic stimulation application on alleviating back pain and maintaining muscle mass in patients with end-stage renal disease.

02

Conditions studied

  • End-Stage Renal Disease
03

In context

Kidney Failure, Chronic

2,108 studies on the registry are indexed under Kidney Failure, Chronic; 273 are open to participants now.

This study's planned enrollment of 18 is below the median of 57 across 1,569 interventional studies indexed under Kidney Failure, Chronic.

Browse Kidney Failure, Chronic studies →

Lead sponsor

Bundang CHA Hospital is the lead sponsor of 35 studies on the registry; 18 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Adults aged 19 years or older
  2. Patients diagnosed with end-stage renal failure and receiving dialysis treatment more than three times a week
  3. Back pain intensity of 4 points or higher on the visual analogue scale (VAS)
  4. Those with cognitive function that can clearly indicate NRS with a score of 23 points or higher, the criterion for determining cognitive impairment on the (MMSE) [14]
  5. Those who voluntarily decided to participate in this clinical trial after receiving a detailed explanation and fully understanding it and gave written consent to comply with the precautions

Exclusion criteria

Exclusion Criteria:

  1. If the pain is due to trauma
  2. If it is difficult to participate in the study due to serious mental illness (e.g. schizophrenia, bipolar disorder, etc.) or psychological instability.
  3. Patients with severe neurological illness (e.g. stroke, severe dementia, etc.).
  4. Those with poor general condition due to unstable cardiovascular, digestive, respiratory, or endocrine systems, or severe internal medical illness such as systemic infection
  5. Patients participating in other therapeutic clinical trials or those who have participated in other therapeutic clinical trials within the past 30 days (observational studies are not relevant)

  6. If there are to magnetic stimulation

    • Patients with implanted medical devices (e.g. pacemakers)
    • Metal objects are inserted into the skull
    • A wound on the skin at the attachment site
    • History of epilepsy
    • Cervical pain or musculoskeletal disease
    • Pregnant and lactating women
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    End-Stage Renal Disease patients

    Device: Effects of applying magnetic stimulation

Interventions

  • DeviceEffects of applying magnetic stimulation

    The Effect of Magnetic Stimulation on Low Back Pain Relief and Muscle Mass Maintenance in Patients with End-Stage Renal Disease (ESRD)

06

What researchers measure

Primary outcomes

  1. Visual Analogue Sclae (VAS)

    An assessment in which the subject quantifies the level of pain numerically from 0 to 10. The higher the number, the more intense the pain.

    Time frame: 7 days before intervention/1 day after intervention/1 month after intervention

Secondary outcomes

  1. Short Physical Performance Battery (SPPB)

    Measures balance, lower extremity strength, and functional ability on a scale of 0 to 16. Higher scores indicate better function.

    Time frame: 7 days before intervention/1 day after intervention/1 month after intervention

  2. The World Health Organization (WHOQOL-BREF)

    The WHOQOL-BREF consists of 26 items, with scores ranging from 1 to 5. A higher score indicates a higher quality of life.

    Time frame: 7 days before intervention/1 day after intervention/1 month after intervention

  3. 3D Motion Capture

    Collecting human body movement data using a 3D infrared camera and ground reaction force device

    Time frame: 7 days before intervention/1 day after intervention/1 month after intervention

  4. Dual Energy X-ray Absorptionmetry (DEXA)

    A test that measures muscle mass by utilizing the energy absorption properties of high-energy and low-energy X-rays.

    Time frame: 7 days before intervention/1 day after intervention/1 month after intervention

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2025 (actual). Primary completion is estimated for Feb 2026, 6 months after the start.

Of 347 non-industry interventional studies with no phase under Kidney Failure, Chronic, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 47. This study's planned 6 months is below that.

Counting every sponsor, half of 425 studies reached it within 23 months; a quarter within 8 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
May 11, 2025
First posted
May 21, 2025
StartActual
Aug 6, 2025
Primary completionEst.
Feb 19, 2026
CompletionEst.
Feb 19, 2026
Last update
Sep 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06982573
Lead sponsor
Bundang CHA Hospital
Responsible party
MinYoung Kim, MD, PhD (Principle investigator, Bundang CHA Hospital) — Principal investigator
First posted
May 21, 2025
Start date
Aug 6, 2025
Primary completion
Feb 19, 2026 (estimated)
Completion
Feb 19, 2026 (estimated)
Last update
Sep 19, 2025

Study contacts

Chung Eun Hye, M.S
Contact
a230419@chamc.co.kr
+821032657071 ext. 8867
Kim Minyoung, M.D., Ph.D
principal investigator · Bundang CHA Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Kidney Failure, Chronic →

Other studies from this sponsor

Bundang CHA Hospital

Start the discussion